- Page 1 and 2:
Immunotherapy for Infectious Diseas
- Page 3 and 4:
In f e c t i o u s . D i s e a s e
- Page 5 and 6:
© 2002 Humana Press Inc. 999 River
- Page 7 and 8:
vi Preface I am grateful to all of
- Page 9 and 10:
viii Contents 11 Passive Immunother
- Page 11 and 12:
x Contributors BARBARA G. MATTHEWS,
- Page 14 and 15:
From: Immunotherapy for Infectious
- Page 16 and 17:
Humoral Immunity 5 Fig. 1. Humoral
- Page 18 and 19:
Humoral Immunity 7 Table 1 Properti
- Page 20 and 21:
Humoral Immunity 9 minal complement
- Page 22 and 23:
Humoral Immunity 11 ficity. In ligh
- Page 24 and 25:
Humoral Immunity 13 Fig. 7. VDJ joi
- Page 26 and 27:
Humoral Immunity 15 Fig. 9. Messeng
- Page 28 and 29:
Humoral Immunity 17 In contrast to
- Page 30 and 31:
Humoral Immunity 19 advantage to tr
- Page 32 and 33:
Humoral Immunity 21 32. Allman DM,
- Page 34 and 35:
Some Basic Cellular Immunology Prin
- Page 36 and 37:
Cellular Immunology Principles 25 i
- Page 38 and 39:
Cellular Immunology Principles 27 s
- Page 40 and 41:
Cellular Immunology Principles 29 d
- Page 42 and 43:
Cellular Immunology Principles 31 f
- Page 44 and 45:
Cellular Immunology Principles 33 F
- Page 46 and 47:
Cellular Immunology Principles 35 R
- Page 48 and 49:
Cellular Immunology Principles 37 1
- Page 50 and 51:
INTRODUCTION Immune Defense at Muco
- Page 52 and 53:
Immune Defense at Mucosal Surfaces
- Page 54 and 55:
Immune Defense at Mucosal Surfaces
- Page 56 and 57:
Immune Defense at Mucosal Surfaces
- Page 58 and 59:
Immune Defense at Mucosal Surfaces
- Page 60 and 61:
Immune Defense at Mucosal Surfaces
- Page 62 and 63:
Immune Defense at Mucosal Surfaces
- Page 64 and 65:
Immune Defense at Mucosal Surfaces
- Page 66 and 67:
Immune Defense at Mucosal Surfaces
- Page 68 and 69:
Immune Defense at Mucosal Surfaces
- Page 70 and 71:
Immune Defense at Mucosal Surfaces
- Page 72:
II Molecular Basis for Immunotherap
- Page 75 and 76:
64 Kunert and Katinger IMMUNOGLOBUL
- Page 77 and 78:
66 Fig. 2. Monomeric, dimeric, and
- Page 79 and 80:
68 Kunert and Katinger Fig. 4. Humo
- Page 81 and 82:
70 Kunert and Katinger remove prote
- Page 83 and 84:
72 Kunert and Katinger Fig. 6. Diff
- Page 85 and 86:
74 Kunert and Katinger persons of a
- Page 87 and 88:
76 Kunert and Katinger that so-call
- Page 89 and 90:
78 Kunert and Katinger whereas sele
- Page 91 and 92:
80 Kunert and Katinger Different pr
- Page 93 and 94:
82 Kunert and Katinger HUMAN/MOUSE
- Page 95 and 96:
84 Kunert and Katinger are expresse
- Page 97 and 98:
86 Kunert and Katinger missing meta
- Page 99 and 100:
88 Kunert and Katinger Fig. 8. Sche
- Page 101 and 102:
90 Kunert and Katinger include a se
- Page 103 and 104:
92 Kunert and Katinger 32. Lee S, e
- Page 105 and 106:
94 Kunert and Katinger 72. Abbs IC,
- Page 107 and 108:
96 Kunert and Katinger 117. Wright
- Page 110 and 111:
From: Immunotherapy for Infectious
- Page 112 and 113:
Dendritic Cells 101 several organis
- Page 114 and 115:
Dendritic Cells 103 tion that infec
- Page 116 and 117:
Dendritic Cells 105 chaperones such
- Page 118 and 119:
Dendritic Cells 107 CD8� CTLs, th
- Page 120 and 121:
Dendritic Cells 109 complete tumor
- Page 122 and 123:
Dendritic Cells 111 19. Holland SM,
- Page 124 and 125:
Dendritic Cells 113 mouse pneumonit
- Page 126 and 127:
Dendritic Cells 115 dendritic cells
- Page 128 and 129:
INTRODUCTION Cytokines, Cytokine An
- Page 130 and 131:
Cytokines, Cytokine Antagonists, an
- Page 132 and 133:
Cytokines, Cytokine Antagonists, an
- Page 134 and 135:
Cytokines, Cytokine Antagonists, an
- Page 136 and 137:
Cytokines, Cytokine Antagonists, an
- Page 138 and 139:
Cytokines, Cytokine Antagonists, an
- Page 140 and 141:
Principles of Vaccine Development F
- Page 142 and 143:
Principles of Vaccine Development 1
- Page 144 and 145:
Principles of Vaccine Development 1
- Page 146 and 147:
Principles of Vaccine Development 1
- Page 148 and 149:
Principles of Vaccine Development 1
- Page 150 and 151:
Principles of Vaccine Development 1
- Page 152 and 153:
Principles of Vaccine Development 1
- Page 154 and 155:
Principles of Vaccine Development 1
- Page 156 and 157:
Principles of Vaccine Development 1
- Page 158:
Principles of Vaccine Development 1
- Page 162 and 163:
INTRODUCTION Immunopathogenesis of
- Page 164 and 165:
Immunopathogenesis of HIV Disease 1
- Page 166 and 167:
Immunopathogenesis of HIV Disease 1
- Page 168 and 169:
Immunopathogenesis of HIV Disease 1
- Page 170 and 171:
Immunopathogenesis of HIV Disease 1
- Page 172:
Immunopathogenesis of HIV Disease 1
- Page 175 and 176:
164 Connick counts ranged from 73 t
- Page 177 and 178:
166 Connick retinitis in an individ
- Page 179 and 180:
168 Connick A novel method of ident
- Page 181 and 182:
170 Connick occurs quite early in i
- Page 183 and 184:
172 Connick 2. Delta Coordinating C
- Page 185 and 186:
174 Connick 39. Hurni MA, Bohlen L,
- Page 187 and 188:
176 Connick 76. Dolan M.J., Clerici
- Page 189 and 190:
178 Connick 114. Komanduri KV, Visw
- Page 192 and 193:
From: Immunotherapy for Infectious
- Page 194 and 195:
Active Immunization for HIV Infecti
- Page 196 and 197:
Active Immunization for HIV Infecti
- Page 198 and 199:
Active Immunization for HIV Infecti
- Page 200 and 201:
Active Immunization for HIV Infecti
- Page 202 and 203:
Active Immunization for HIV Infecti
- Page 204 and 205:
Active Immunization for HIV Infecti
- Page 206 and 207:
Active Immunization for HIV Infecti
- Page 208:
Active Immunization for HIV Infecti
- Page 211 and 212: 200 Jacobson changes of gp120 alter
- Page 213 and 214: 202 Jacobson is reduced (54,55). A
- Page 215 and 216: 204 Jacobson Table 2 Potential Prot
- Page 217 and 218: 206 Jacobson from the SIV/17E-Cl-in
- Page 219 and 220: 208 Jacobson Several groups have de
- Page 221 and 222: 210 Jacobson HUMAN STUDIES Polyclon
- Page 223 and 224: 212 Jacobson clinical isolates, whi
- Page 225 and 226: 214 Jacobson 22. Beasley RP, Hwang
- Page 227 and 228: 216 Jacobson 59. Yoshiyama H, Mo H,
- Page 229 and 230: 218 Jacobson 95. Prince AM, Reesink
- Page 231 and 232: 220 Jacobson 133. Stiehm ER, Lamber
- Page 233 and 234: 222 Kilby and Bucy Although clinica
- Page 235 and 236: 224 Kilby and Bucy can infect human
- Page 237 and 238: 226 Kilby and Bucy the proinflammat
- Page 239 and 240: 228 Kilby and Bucy CD3/CD28, and th
- Page 241 and 242: 230 Kilby and Bucy of viral replica
- Page 243 and 244: 232 Kilby and Bucy 21. Cao Y, Qin L
- Page 245 and 246: 234 Kilby and Bucy 64. Pantaleo G,
- Page 247 and 248: 236 Kilby and Bucy 101. Clements-Ma
- Page 249 and 250: 238 Dornburg and Pomerantz cells (5
- Page 251 and 252: 240 Dornburg and Pomerantz Fig. 2.
- Page 253 and 254: 242 Dornburg and Pomerantz domains
- Page 255 and 256: 244 Dornburg and Pomerantz GENETIC
- Page 257 and 258: 246 Dornburg and Pomerantz Fig. 5.
- Page 259: 248 Dornburg and Pomerantz 6. Balti
- Page 263 and 264: 252 Onorato and Pollard However, th
- Page 265 and 266: 254 Onorato and Pollard patients wi
- Page 267 and 268: 256 Onorato and Pollard Another imm
- Page 269 and 270: 258 Onorato and Pollard 26. Guidott
- Page 271 and 272: 260 Sili, Heslop, and Rooney Fig. 1
- Page 273 and 274: 262 Sili, Heslop, and Rooney Fig. 2
- Page 275 and 276: 264 Sili, Heslop, and Rooney immuno
- Page 277 and 278: 266 Sili, Heslop, and Rooney Fig. 3
- Page 279 and 280: 268 Sili, Heslop, and Rooney Human
- Page 281 and 282: 270 Sili, Heslop, and Rooney CONCLU
- Page 283 and 284: 272 Sili, Heslop, and Rooney 32. Ba
- Page 285 and 286: 274 Sili, Heslop, and Rooney 73. va
- Page 287 and 288: 276 Donta no controlled clinical tr
- Page 289 and 290: 278 Donta antibody preparation (HA-
- Page 291 and 292: 280 Donta 16. Salcedo J, Keates S,
- Page 294 and 295: INTRODUCTION From: Immunotherapy fo
- Page 296 and 297: Tuberculosis and Other Mycobacteria
- Page 298 and 299: Tuberculosis and Other Mycobacteria
- Page 300 and 301: Tuberculosis and Other Mycobacteria
- Page 302 and 303: Tuberculosis and Other Mycobacteria
- Page 304 and 305: Tuberculosis and Other Mycobacteria
- Page 306 and 307: Tuberculosis and Other Mycobacteria
- Page 308 and 309: Tuberculosis and Other Mycobacteria
- Page 310 and 311:
Tuberculosis and Other Mycobacteria
- Page 312 and 313:
Tuberculosis and Other Mycobacteria
- Page 314 and 315:
From: Immunotherapy for Infectious
- Page 316 and 317:
Fungal Infections 305 Table 2 Categ
- Page 318 and 319:
Fungal Infections 307 rapid bone ma
- Page 320 and 321:
Fungal Infections 309 has activity
- Page 322 and 323:
311 Table 4 Case Reports of Unusual
- Page 324 and 325:
Fungal Infections 313 randomized co
- Page 326 and 327:
Fungal Infections 315 the administr
- Page 328 and 329:
Fungal Infections 317 modalities in
- Page 330 and 331:
Fungal Infections 319 35. Vecchiare
- Page 332 and 333:
Fungal Infections 321 74. Han Y, Cu
- Page 334 and 335:
Index 323 A ADCC, see Antibody-depe
- Page 336 and 337:
Index 325 immunotherapy clinical tr
- Page 338 and 339:
Index 327 function, 32, 33, 182-185
- Page 340 and 341:
Index 329 secretory immunoglobulin
- Page 342 and 343:
Index 331 dendritic cell response,